Merck gets first FDA nod for Keytruda in breast cancer setting

This article was originally published here

Keytruda (pembrolizumab), an anti-PD-1 therapy, works by enhancing the ability of the body’s immune system to identify and fight tumour cells. It is a humanised monoclonal antibody that

The post Merck gets first FDA nod for Keytruda in breast cancer setting appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply